The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.
Fifteen patients with primary Raynaud's phenomenon received captopril 25 mg or placebo, three times daily for 6 weeks, in a randomized double-blind cross-over study. Compared with placebo, captopril produced a significant improvement in cutaneous blood flow but did not alter the frequency or severity of attacks of Raynaud's phenomenon.
Rustin
M H
MH
Department of Dermatology, Middlesex Hospital, London, U.K.
Almond
N E
NE
Beacham
J A
JA
Brooks
R J
RJ
Jones
D P
DP
Cooke
E D
ED
Dowd
P M
PM
D000328:Adult; D002216:Captopril / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D011897:Random Allocation; D011928:Raynaud Disease / Q000188:drug therapy* / Q000503:physiopathology; D012039:Regional Blood Flow / Q000187:drug effects; D012867:Skin / Q000098:blood supply*
D002216:Captopril